Robert V. Toni, President & CEO

Benny Ward, CFO

CLOSURE Medical Corporation

(919) 876-7800


For General Info: Stuart Levine (212) 661-8030

For Analyst Info: Cecelia Heer (212) 661-8030

For Media Info: Deanne Eagle (212) 661-8030



CLOSURE Medical Schedules Date for Third-Quarter

Financial Results and Conference Call


RALEIGH, N.C., October 23, 2000 -- CLOSURE Medical Corporation (Nasdaq: CLSR - news), today said that it intends to release, on October 26, 2000, financial results for the third quarter and nine months ended September 30, 2000. In conjunction with this release, CLOSURE will host a conference call that will be broadcast simultaneously over the Internet at 4:00 p.m. EST on October 26, 2000. The live call and replay can be accessed via the Internet at .

Separately, CLOSURE also said it has been invited to give a presentation at 4:25 p.m. at the CIBC Health Care Conference on October 23rd in New York.


CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina, develops, manufactures, and commercializes medical tissue adhesive products based on its proprietary cyanoacrylate technology. CLOSURE's nonabsorbable tissue adhesive products may be used to replace sutures and staples for certain topical wound closure applications, while its internal tissue adhesive products can potentially be used for internal wound closure and management. Currently marketed nonabsorbable tissue adhesive products include DERMABOND®* Topical Skin Adhesive, which is used to replace sutures and staples for closure of certain lacerations and incisions; OCTYLDENT®* adhesive, which is used as an adjunct in the treatment of adult periodontal disease; and the NEXABAND®* line of topical adhesives, which are used in veterinary wound closure and management.


This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties or other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward-looking statements. These factors include, but are not limited to the early stage of commercialization of the Company products; the progress of its research and development programs for future products; the need for regulatory approval and effects of governmental regulation; technological uncertainties; dependence on marketing partners, and dependence on patents and trade secrets, as well as those detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 1999 filed with the Securities and Exchange Commission.